You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 億帆醫藥漲9% 在研新藥達到預設評價標準
格隆匯 01-06 11:11
格隆匯1月6日丨億帆醫藥(002019.SZ)現漲9%,報16.95元,暫成交5.15億元,最新總市值210億。公司昨日公告稱,在研品種重組人粒細胞集落刺激因子-Fc融合蛋白(F-627)中國III期臨牀試驗的有效性結果已全面達到臨牀試驗預設評價標準,療效與對照藥物(原研進口藥物重組人粒細胞集落刺激因子)相當。另外,F-627的整體安全性良好,較對照藥物,不良事件發生率及嚴重程度等方面均無明顯差異,與F-627相關的不良反應多為輕中度,表明F-627具有良好的安全性和耐受性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account